Your session is about to expire
← Back to Search
Tenecteplase for Thrombolysis (TIMELESS Trial)
TIMELESS Trial Summary
This trial will compare the effectiveness of a clot-busting drug to a placebo in people who have had a stroke. All participants will also receive the standard care for a stroke.
TIMELESS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 3 trial • 223 Patients • NCT00396253TIMELESS Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you please give me the total number of hospitals that are participating in this trial?
"Currently, there are 48 patients enrolled in this trial taking place at McLaren Flint in Flint, Uni of Alberta in Edmonton, Providence Portland Medical Center in Portland, and other locations."
Are there empty slots in this clinical trial that new patients could fill?
"That is correct, the public clinical data indicates that this research is currently enrolling patients. This trial was first announced on March 2nd, 2019 and was most recently updated on October 27th, 2022. The total number of patients needed for this study is 456, which will be recruited from 48 different sites."
Could you share any other notable studies that have used Tenecteplase?
"There are 426 clinical trial sites for Tenecteplase around the world, with 15 of those being active at this time. Of the active trials, 12 are in Phase 3."
Has Tenecteplase been cleared by the FDA?
"There is a significant amount of data surrounding Tenecteplase's safety, as this is a Phase 3 trial. This drug received a score of 3."
Share this study with friends
Copy Link
Messenger